A Placebo-controlled, Double-blind, Randomized Trial to Compare the Effect of Different Doses of ALN-PCSSC Given as Single or Multiple Subcutaneous Injections in Subjects With High Cardiovascular Risk and Elevated LDL-C

Trial Profile

A Placebo-controlled, Double-blind, Randomized Trial to Compare the Effect of Different Doses of ALN-PCSSC Given as Single or Multiple Subcutaneous Injections in Subjects With High Cardiovascular Risk and Elevated LDL-C

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Jun 2018

At a glance

  • Drugs Inclisiran (Primary)
  • Indications Hypercholesterolaemia
  • Focus Therapeutic Use
  • Acronyms ORION; ORION-1
  • Sponsors The Medicines Company
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 26 Jun 2018 Results presented at the 78th Annual Scientific Sessions of the American Diabetes Association
    • 26 Jun 2018 Results presented in a media release by The Medicines Company.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top